Drug Profile
SAS
Alternative Names: SAS - BioMAS; SAS - FeramdaLatest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Bar-Ilan University
- Developer BioMAS; Feramda
- Class Eye disorder therapies; Organometallic compounds; Small molecules
- Mechanism of Action Integrin alpha4beta1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Age-related macular degeneration; Psoriasis
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in Israel
- 01 Jan 2020 Preclinical trials in Age-related macular degeneration in Israel before January 2020 (Feramda pipeline, January 2020)
- 28 Nov 2019 No recent reports of development identified for preclinical development in Psoriasis in Israel (Topical)